Sugammadex
From WikiAnesthesia
Revision as of 07:00, 21 February 2021 by Chris Rishel (talk | contribs)
Sugammadex
| Trade names |
Bridion |
|---|---|
| Clinical data | |
| Uses |
Reversal of neuromuscular blockade from rocuronium and vecuronium |
| Contraindications |
Renal impairment |
| Routes of administration |
Intravenous |
| Dosage |
Based upon response to train-of-four stimulation:
Reversal immediately after administration of rocuronium 1.2 mg/kg: 16 mg/kg |
| Pharmacodynamics | |
| Mechanism of action |
Encapsulation of rocuronium or vecuronium |
| Adverse effects |
Bradycardia, may interfere with hormonal contraceptives |
| Pharmacokinetics | |
| Physical and chemical data | |
| Formula |
C72H112O48S8 |
| Molar mass |
2002.12 g/mol |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Sugammadex is used to reverse neuromuscular blockade from rocuronium and vecuronium.
Uses
If a patient requires reparaylsis after administration of sugammadex (up to 4 mg/kg), rocuronium or vecuronium can be re-administered after a minimum waiting time.[1]
| Drug and dose to be administered | Minimum waiting time |
|---|---|
| Rocuronium 1.2 mg/kg | 5 minutes |
| Rocuronium 0.6 mg/kg or
vecuronium 0.1 mg/kg |
4 hours |
Contraindications
Absolute contraindications
Precautions
Pharmacology
Pharmacodynamics
Mechanism of action
Adverse effects
Pharmacokinetics
Chemistry and formulation
History
References
Top contributors: Chris Rishel and Tymoteusz Kajstura